Clinical trials: Stomach Diseases
GERD (Gastroesophageal Reflux Disease), NERD
New Topical tReatment Options for Symptomatic patiEnts With Nonerosive gastroesophageaL Reflux dIsease (The RELIEF Trial)
The goal of this randomized, double-blind, single-center clinical trial RELEIF is to learn if medical devices work to decrease symptoms of gastroesophageal reflux disease (GERD) in adults' patients.
- Conditions
- GERD (Gastroesophageal Reflux Disease), NERD, Heartburn, Regurgitation, Gastric
- Trial name
- RELIEF (NCT07624383)
- Testing
- Esophageal barrier medical device
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Cellmedis
Gastric Cancer, Gastroesophageal Junction Cancer
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
The main objectives of this study are to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies, and to evaluate the efficacy of bemarituzumab in combination with S-1 and oxaliplatin…
- Trial name
- FORTITUDE-103 (NCT05322577)
- Testing
- Bemarituzumab, CAPOX, SOX
- Where
- 42 sites in United States, Japan and 3 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of…
- Trial name
- NCT01260194
- Testing
- trastuzumab [Herceptin]
- Where
- 6 sites in India
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Gastric Neoplasms, Pancreatic Neoplasms
Chromogranin A as Blood Marker in Cancer Patients
Gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) are a heterogenous group of neoplasms that arise from enterochromaffin cells of the gastrointestinal (GI) tract and pancreas. They account for 50-70% of all incident NETs.
- Conditions
- Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03817866
- Testing
- BRAHMS CgA II KRYPTOR
- Where
- 4 sites in United States, Germany
- Volunteers
- 175 people
- Sponsor
- Brahms AG
Familial Adenomatous Polyposis
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.
- Trial name
- NCT03806426
- Testing
- Eicosapentaenoic acid free fatty acid (EPA-FFA)
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- S.L.A. Pharma AG
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.
- Trial name
- NCT01508923
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- Novo Nordisk A/S
HER2-expressing Cancers
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable)…
- Trial name
- NCT02892123
- Testing
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Jazz Pharmaceuticals
Gastroesophageal Reflux, Heartburn
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.
- Trial name
- NCT00216489
- Testing
- rabeprazole sodium
- Volunteers
- 191 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be…
- Trial name
- NCT02086968
- Testing
- Injectafer, Ferrous Sulfate tablets
- Volunteers
- 198 people
- Sponsor
- American Regent, Inc.
Gastric Cancer
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
The purpose of study is to evaluate the efficacy and safety of ONO-4538 in patients with unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard…
- Trial name
- NCT02267343
- Testing
- ONO-4538
- Where
- 49 sites in Japan, South Korea and 1 more
- Volunteers
- 493 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Gastric Ulcer, Duodenal Ulcer
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term low-dose aspirin therapy will be investigated.
- Trial name
- NCT01568398
- Testing
- TAK-438
- Where
- 19 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Chronic Gastritis Caused by Helicobacter Pylori
Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis
H. pylori positive patient volunteers that passed the selection criteria are recruited and divided into a test and a control group.
- Trial name
- NCT02721355
- Testing
- GastimunHP
- Where
- Vietnam
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Immunology Research Institute in Gifu
Gastroparesis
Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis
This protocol is designed to validate use of the SPM for diagnosis of delayed gastric emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study on patient management in the gastroparetic…
- Trial name
- NCT02022826
- Testing
- SmartPill Monitoring System
- Where
- 11 sites in United States
- Volunteers
- 167 people
- Sponsor
- Medtronic - MITG
Morbid Obesity
Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety
The purpose of this protocol is to determine how band fill volumes that are based on intraband pressure readings can influence the comfortability of the band and to compare weight loss with this methodology to weight loss with…
- Trial name
- NCT00960843
- Testing
- Intraband pressure recording system, Conventional Adjustment
- Where
- 2 sites in Australia, Czechia
- Volunteers
- 51 people
- Sponsor
- Ethicon Endo-Surgery
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.